Prediction and early diagnosis of preeclampsia: scientific perspectives and clinical opportunities


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Preeclampsia (PE) is a clinical syndrome specific to pregnancy and the postpartum period, which complicates 3-8% of all pregnancies, is the main cause of maternal and perinatal morbidity and mortality, and reduces quality of life in a woman even with a successful labor outcome. This review presents an update on the possibilities for early prediction of preeclampsia. It includes scientific publications by foreign and Russian authors for the last 10 years, which have been found in the Pubmed database and other available search platforms: Cochrane, Web of Science, MEDLINE, and Google Scholar. The review gives information on the current results of studying the pathogenesis of preeclampsia and searching for its molecular predictors, by using postgenomic technologies, genome-wide association studies (GWAS), and epigenetics. Conclusion: Further investigations are needed to search for and validate the laboratory markers of PE both to predict and prevent the risk of developing severe forms of this condition.

Full Text

Restricted Access

About the authors

Zulfiya S. Khodzhaeva

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: zkhodjaeva@mail.ru
M.D., Professor, Deputy Director of Obstetrics Institute

Madina S. Oshkhunova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: madina.oshkhunova@mail.ru
graduate student of the High Risk Pregnancy Department

Kamilla T. Muminova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: kamika9l@mail.ru
PhD, Researcher of the High Risk Pregnancy Department

Kseniia A. Gorina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: kseniiagorina@gmail.com
PhD, Researcher of the High Risk Pregnancy Department

Alexey M. Kholin

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_kholin@oparina4.ru
PhD, Head of the Telemedicine Section of the Department of Regional Cooperation and Integration

References

  1. Nan L., Yu-Na G., Li-Kun G., Bing-Shun W. Advances in biomarker development and potential application for preeclampsia based on pathogenesis. Eur. J. Obstet. Gynecol. Reprod. Biol. X. 2021; 9: 100-19. https://dx.doi.org/10.1016/j.eurox.2020.100119.
  2. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. WHO; 2015: 1-48.
  3. Kucukgoz U.G., Ozgunen F.T., Buyukkurt S., Guzel A.B., Urunsak I.F., Demir S.C., Evruke I.C. Comparison of clinical and laboratory findings in earlyand late-onset preeclampsia. J. Matern. Fetal Neonatal Med. 2013; 26(12): 1228-33. https://dx.doi.org/10.3109/14767058.2013.776533.
  4. Raymond D., Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet. Gynecol. Surv. 2011; 66(8): 497-506. https://dx.doi.org/10.1097/OGX.0b013e3182331028.
  5. Stubert J., Ullmann S., Dieterich M., Diedrich D., Reimer T. Clinical differences between earlyand late-onset severe preeclampsia and analysis of predictors for perinatal outcome. J. Perinat. Med. 2014; 42(5): 617-27. https://dx.doi.org/10.1515/jpm-2013-0285.
  6. Ходжаева З.С., Холин А.М., Вихляева Е.М. Ранняя и поздняя пре-эклампсия: парадигмы патобиологии и клиническая практика. Акушерство и гинекология. 2013; 10: 4-11. Khodzhaeva Z.S., Kholin A.M., Vikhlyaeva E.M. Early and late preeclampsia: Pathobiology paradigms and clinical practice. Obstetrics and Gynegology. 2013; 10: 4-11. (in Russian)].
  7. Sun C.J., Li L., Li X.Y., Zhang W.Y., Liu X.W. Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. Arch. Gynecol. Obstet. 2018; 298(1): 125-32. https://dx.doi.org/10.1007/s00404-018-4791-8.
  8. Youssef L., Simoes R.V., Jezid Miranda J., Garcia-Martin M.L., Paules С., Crovetto F. et al. Paired maternal and fetal metabolomics reveal a differential fingerprint in preeclampsia versus fetal growth restriction. Sci. Rep. 2021; 11(1): 14422. https://dx.doi.org/10.1038/s41598-021-93936-9.
  9. Муминова К.Т., Ходжаева З.С., Шмаков Р.Г., Баранов И.И., Кононихин А.С.,Стародубцева Н.Л., Франкевич В.Е., Холин А.М. Факторы риска и возможные предикторы преэклампсии на основании протеом-ного (пептидомного) анализа мочи. Акушерство и гинекология: новости, мнения, обучение. 2020; 8(4): 8-12.
  10. Opichka M.A., Rappelt M.W., Gutterman D.D., Grobe J.L., McIntosh J.J. Review vascular dysfunction in preeclampsia. Cells. 2021; 10(11): 3055. https://dx.doi.org/10.3390/cells10113055.
  11. Сидорова И.С., Никитина Н.А. Научно обоснованная система прогнозирования преэклампсии. Акушерство и гинекология. 2017; 3: 55-61. https://dx.doi.org/10.18565/aig.2017.3.55-61.
  12. Chaemsaithong P., Sahota D.S., Poon L.C. First trimester preeclampsia screening and prediction. Am. J. Obstet. Gynecol. 2022; 226(2): 1071-97. https://doi.org/10.1016/j.ajog.2020.07.020.
  13. Zeisler H., Llurba E., Chantraine F., Vatish M., Staff A. C., Sennstrom M. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 2016; 374(1): 13-22. https://dx.doi.org/10.1056/NEJMoa1414838.
  14. Hadker N., Garg S., Costanzo C., van der Helm W., Creeden J. Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective. Hypertens. Pregnancy. 2013; 32(2): 105-19. https://dx.doi.org/10.3109/10641955.2011.638958.
  15. Tan M.Y., Syngelaki А., Poon L.C., Rolnik D.L., O'Gorman N. Delgado J.L. et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2018; 52(2): 186-95. https://dx.doi.org/10.1002/uog.19112.
  16. O’Gorman N., Wright D., Syngelaki A., Akolekar R., Wright А., Poon L.C., Nicolaides K.H. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am. J. Obstet. Gynecol. 2016; 214(1): 103.E1-12. https://dx.doi.org/10.1016/j.ajog.2015.08.034.
  17. O’Gorman N., Wright D., Poon L.C., Rolnik D.L., Syngelaki A., Wright A. et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2017; 49(6): 751-5. https://dx.doi.org/10.1002/uog.17399.
  18. Deshpande J.S., Sundrani D.P., Sahay A.S., Gupte S.A., Joshi S.R. Unravelling the potential of angiogenic factors for the early prediction of preeclampsia. Hypertens. Res. 2021; 44(7): 756-69. https://dx.doi.org/10.1038/s41440-021-00647-9.
  19. Gray K.J., Kovacheva V.P., Mirzakhani H., Bjonnes A.C., Almoguera B., Wilson M.L. et al. Risk of pre-eclampsia in patients with a maternal genetic predisposition to common medical conditions: a case-control study. BJOG. 2021; 128(1): 55-65. https://dx.doi.org/10.1111/1471-0528.16441.
  20. Gray K.J., Saxena R., Karumanchi S.A. Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. Am. J. Obstet. Gynecol. 2018; 218(2): 211-8. https://dx.doi.org/10.1016/j.ajog.2017.11.562.
  21. McGinnis R., Steinthorsdottir V., Williams N., Thorleifsson G., Shooter S., Hjartardottiret S. et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. Nat. Genet. 2017; 49(8): 1255-60. https://dx.doi.org/10.1038/ng.3895.
  22. Gray K.J., Kovacheva V.P., Mirzakhani H., Bjonnes A.C., Almoguera B., DeWan A.T. et al. Gene-centric analysis of preeclampsia identifies maternal association at PLEKHG1. Hypertension. 2018; 72(2): 408-16. https://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10688.
  23. Reidy K.J., Hjorten R.C., Simpson C.L., Rosenberg A.Z., Rosenblum S.D., Kovesdy C.P. et al. Fetal-Not Maternal-APOL1 genotype associated with risk for preeclampsia in those with African Ancestry. Am. J. Hum. Genet. 2018; 103(3): 367-76. https://dx.doi.org/10.1016/j.ajhg.2018.08.002.
  24. Johnson M.P., Roten L.T., Dyer T.D., East C.E., Forsmoet S., Blangero J. et al. The ERAP2 gene is associated with preeclampsia in Australian and Norwegian populations. Hum. Genet. 2009; 126(5): 655-66. https://dx.doi.org/10.1007/s00439-009-0714-х
  25. Sun C.J., Li L., Li X., Zhang WY., Liu X.W. Novel SNPs ofWNK1 and AKR1C3 are associated with preeclampsia. Gene. 2018; 668: 27-32. https://dx.doi.org/10.1016/j.gene.2018.05.055.
  26. Zhao L., Bracken M.B., DeWan A.T. Genome-wide association study of pre-eclampsia detects novel maternal single nucleotide polymorphisms and copy-number variants in subsets of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohort. Ann. Hum. Genet. 2013; 77(4): 277-87. https://dx.doi.org/10.1111/ahg.12021.
  27. Steinthorsdottir V., McGinnis R., Williams N.O., Stefansdottir L., Thorleifsson G., Shooter S. et al. Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nat. Commun. 2020; 11(1): 59-76. https://dx.doi.org/10.1038/s41467-020-19733-6.
  28. Zhang L., Cao Z., Feng F., Xu Y.N., LiL., Gao H. A maternal GOT1 novel variant associated with early-onset severe preeclampsia identified by whole-exome sequencing. BMC Med. Genet. 2020; 20(1): 49. https://dx.doi.org/10.1186/s12881-020-0989-2.
  29. Whitehead C.L., Walker S.P., Ye L., Mendis S., Kaitu'u-Lino T.J., Lappas M., Tong S. Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. J. Clin. Endocrinol. Metab. 2013; 98(3): 429-36. https://dxdoi.org/10.1210/jc.2012-2468.
  30. Song X., Luo X., Gao Q., Wang Y.,Gao O., Long W. Dysregulation of LncRNAs in placenta and pathogenesis of preeclampsia. Curr. Drug Targets. 2017; 18(10): 1165-70. https://dx.doi.org/10.2174/1389450118666170404160000.
  31. Lv. Y., Lu Ch., Ji X., Miao Z., Long W., Ding H., Lv M. Roles of microRNAs in preeclampsia. J. Cell. Physiol. 2019; 234(2): 1052-61. https://dx.doi.org/10.1002/jcp.27291.
  32. Xu P., Ma Y., Wu H., Wang Y.L. Placenta-derived microRNAs in the pathophysiology of human pregnancy. Front. Cell Dev. Biol. 2021; 9: 646326. https://dx.doi.org/10.3389/fcell.2021.646326.
  33. Morales-Prieto D.M., Ospina-Prieto S., Schmidt A., Chaiwangyen W., Markert U.R. Elsevier Trophoblast Research Award Lecture: origin, evolution and future of placenta miRNAs. Placenta. 2014; 35(Suppl. 1): S39-45. https://dx.doi.org/10.10167j.placenta.2013.11.017.
  34. Khodzhaeva Z., Kogan E., Demura T., Akatyeva A., Vavina O., Savonova A., Kholin A., Sukhikh G. [206-POS]: Morphological/immunohistochemical alterations of endometrial and placental site areas in preeclampsia. Pregnancy Hypertens. 2015; 1(5): 103-4. https://dx.doi.org/10.1016/j.preghy.2014.10.212.
  35. Biro O., Nagy B., Rigo J. Identifying miRNA regulatory mechanisms in preeclampsia by systems biology approaches. Hypertens. Pregnancy. 2017; 36(1): 90-9. https://dx.doi.org/10.1080/10641955.2016.1239736.
  36. Luo R., Wang Y., Xu P., Cao G., Zhao Y. Shao X. et al. Hypoxia-inducible miR-210 contributes to preeclampsia via targeting thrombospondin type I. domain containing 7A. Sci. Rep. 2016; 6: 19588. https://dx.doi.org/10.1038/srep19588.
  37. Brooks S.A., Martin E., Smeester L., Grace M.R., Boggess K., Fry R.C. miRNAs as common regulators of the transforming growth factor (TGF)-P pathway in the preeclamptic placenta and cadmium-treated trophoblasts: Links between the environment, the epigenome and preeclampsia. Food Chem. Toxicol. 2016; 98(Pt A): 50-7. https://dx.doi.org/10.1016/j.fct.2016.06.023.
  38. Srinivasan S., Treacy R., Herrero T., Olsen R., Leonardo T.R. et al. Discovery and verification of extracellular miRNA biomarkers for Non-invasive prediction of pre-eclampsia in asymptomatic women. Cell Reports Med. 2020; 1(2): 100-13. https://dx.doi.org/10.1016/j.xcrm.2020.100013.
  39. Rasmussen M., Reddy M., Nolan R., Camunas-Soler J., Khodursky A., Scheller N.M. et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022; 601(7893): 422-7. https://dx.doi.org/10.1038/s41586-021-04249-w.
  40. Hemmatzadeh M., Shomali N., Yousefzadeh Y., Mohammadi H., Ghasemzadeh A., Yousefi М. MicroRNAs: Small molecules with a large impact on pre-eclampsia. J. Cell. Physiol. 2020; 235(4): 3235-48. https://dx.doi.org/10.1002/jcp.29286.
  41. Tsang J.C.H., Vong J.S.L., Ji L., Poon L.C.Y., Jiang P., Lui K. et al. Integrative single-cell and cell-free plasma RNA transcriptomics elucidates placental cellular dynamics. Proc. Natl. Acad. Sci. USA. 2017; 114(37): E7786-95. https://dx.doi.org/10.1073/pnas.1710470114.
  42. Tarca A.L., Romero R., Erez O., Gudicha D.W., Gabor Than N., Benshalom-Tirosh N. et al. Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. J. Matern. Neonatal Med. 2021; 34(21): 3463-74. https://dx.doi.org/10.1080/14767058.2019.1685964.
  43. Dupont C., Armant D.R., Brenner C.A. Epigenetics: definition, mechanisms and clinical perspective. Semin. Reprod. Med. 2009; 27(5): 351-7. https://dx.doi.org/10.1055/s-0029-1237423.
  44. Yeung K.R., Chiu C.L., Pidsley R., Makris A., Hennessy A., Lind J.M. DNA methylation profiles in preeclampsia and healthy control placentas. Am. J. Physiol. Heart Circ. Physiol. 2016; 310(10): H1295-303. https://dx.doi.org/10.1152/ajpheart.00958.2015.
  45. Feil R., Fraga M.F. Epigenetics and the environment: emerging patterns and implications. Nat. Rev. Genet. 2012; 13(2): 97-109. https://dx.doi.org/10.1038/nrg3142.
  46. Walsh S.W., Nugent W.H., Archer K.J., Dulaimi M.A., Washingtone S.L., Strauss J.F. 3rd. Epigenetic regulation of interleukin-17-related genes and their potential roles in neutrophil vascular infiltration in preeclampsia. Reprod. Sci. 2022; 29(1): 154-62. https://dx.doi.org/10.1007/s43032-021-00605-3.
  47. Cruz J. de O., Conceigao I., Sandrim V.S., Luizon M.R. Comprehensive analyses of DNA methylation of the TIMP3 promoter in placentas from early-onset and late-onset preeclampsia. Placenta. 2022; 117: 118-21. https://dx.doi.org/10.1016/j.placenta.2021.12.003.
  48. Liang L., Rasmussen M.-L., Bening B., Shen X., Chen S., Rost H. et al. Metabolic dynamics and prediction of gestational age and time to delivery in pregnant women. Cell. 2020; 181(7): 1680-92. https://dx.doi.org/10.1016/j.cell.2020.05.002.
  49. Nikolov A., Popovski N. Role of gelatinases mmp-2 and mmp-9 in healthy and complicated pregnancy and their future potential as preeclampsia biomarkers. Diagnostics. 2021; 11(3): 480. https://dx.doi.org/10.3390/diagnostics11030480.
  50. Law K.P., Han T.-L., Tong Ch., Baker P. Mass spectrometry-based proteomics for pre-eclampsia and preterm birth. International J. Mol. Sci. 2015; 16(5): 10952- 85. https://dx.doi.org/10.3390/ijms160510952.
  51. Bujold E., Fillion A., Roux-Dalvai F., Scott-Boyer M.P., Giguere Y., Forest J.C. et al. Proteomic analysis of maternal urine for the early detection of preeclampsia and fetal growth restriction. J. Clin. Med. 2021; 10(20): 4679. https://dx.doi.org/10.3390/jcm10204679.
  52. Tarca A.L., Romero R., Benshalom-Tirosh N., Gabor Than N., Gudicha D.W., Erez O. The prediction of early preeclampsia: results from a longitudinal proteomics study. PLoS One. 2019; 14(6): 0217273. https://dx.doi.org/10.1371/journal.pone.0217273.
  53. Erez O., Romero R., Maymon E., Chaemsaithong P., Done B., Pacora P. et al. The prediction of late-onset preeclampsia: results from a longitudinal proteomics study. PLoS One. 2017; 12(7): 0181468. https://dx.doi.org/10.1371/journal.pone.0181468.
  54. Муминова К.Т., Кононихин А.С., Ходжаева З.С., Шмаков Р.Г., Сергеева В.А. Дифференциальная диагностика гипертензивных состояний во время беременности при помощи анализа пептидомного профиля мочи. Акушерство и гинекология. 2018; 8: 66-75. https://dx.doi.org/10.18565/aig.2018.8.66-75.
  55. Starodubtseva N., Nizyaeva N., Baev O., Bugrova A., Gapaeva M., Muminova K., Kononikhin A., Frankevich V., Nikolaev E., Sukhikh G. SERPINA1 peptides in urine as a potential marker of preeclampsia severity. Int. J. Mol. Sci. 2020; 21(3): 914. https://dx.doi.org/10.3390/ijms21030914.
  56. Bahado-Singh R.O., Syngelaki A., Mandal R., Graham S.F., Akolekar R., Han B. et al. Metabolomic determination of pathogenesis of late-onset preeclampsia. J. Matern. Fetal Neonatal Med. 2017; 30(6): 658-64. https://dx.doi.org/10.1080/14767058.2016.1185411.
  57. Austdal M., Tangeras L.H., Skrastad R.B., Salvesen K.A., Austgulen R., Iversen A.C., Bathen T.F. First trimester urine and serum metabolomics for prediction of preeclampsia and gestational hypertension: a prospective screening study. Int. J. Mol. Sci. 2015; 16(9): 21520-38. https://dx.doi.org/10.3390/ijms160921520.
  58. Koster M.P.H., Vreeken R.J., Harms A.C., Dane A.D., Kuc S., Schielen PC. et al. First-Trimester serum acylcarnitine levels to predict preeclampsia: a metabolomics approach. Dis. Markers. 2015; 2015: 8571108. https://dx.doi.org/10.1155/2015/857108.
  59. Bahado-Singh R.O., Syngelaki А., Akolekar R., Mandal R., Bjondahl T.C., Han B. et al. Validation of metabolomic models for prediction of early-onset preeclampsia. Am. J. Obstet. Gynecol. 2015; 213(4): 530.e1-530.e10. https://dx.doi.org/10.1016/j.ajog.2015.06.044.
  60. Odibo A.O., Goetzinger K.R., Odibo L., Cahill A.G., Macones G.A., Dietzen D.J. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat. Diagn. 2011; 31(10): 990-4. https://dx.doi.org/10.1002/pd.2822.
  61. Austdal M., Thomsen L.C.V., Tangeras L.H., Skei B., Mathew S., Bj0rge L. et al. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics. Placenta. 2015; 36(12): 1455-62. https://dx.doi.org/10.1016/j.placenta.2015.10.019.
  62. Walejko J.M., Chelliah A., Keller-Wood M., Gregg A., Edison A.S. Global metabolomics of the placenta reveals distinct metabolic profiles between maternal and fetal placental tissues following delivery in non-labored women. Metabolites. 2018; 8(1): 10. https://dx.doi.org/10.3390/metabo8010010.
  63. Bahado-Singh R., Poon L.C., Yilmaz A., Syngelaki A., Turkoglu O., Kumar P. et al. Integrated proteomic and metabolomic prediction of term preeclampsia. Sci. Rep. 2017; 7(1). 16189. https://dx.doi.org/10.1038/s41598-017-15882-9.
  64. Youssef L., Crovetto F., Simoes R.V., Miranda J., Paules C. et al. The interplay between pathophysiological pathways in early-onset severe preeclampsia unveiled by metabolomics. Life (Basel). 2022; 12(1): 86. https://dx.doi.org/10.1038/s41598-017-15882-9.
  65. Baylis C., Beinder E., Suto T., August P. Recent insights into the roles of nitric oxide and renin angiotensin in the pathophysiology of preeclamptic pregnancy. Semin. Nephrol. 1998; 18(2): 208-30.
  66. Turner E., Brewster J.A., Simpson N., Walker J.J., Fisher J. Aromatic amino acid biomarkers of preeclampsia - a nuclear magnetic resonance investigation. Hypertens. Pregnancy. 2008; 27(3): 225-35. https://dx.doi.org/10.1080/10641950801955725.
  67. Prokopieva V.D., Yarygina E.G., Bokhan N.A., Ivanova S.A. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies. Oxid. Med. Cell. Longev. 2016; 2016: 2939087. https://dx.doi.org/10.1155/2016/2939087.
  68. Youssef L., Erlandsson L., Akerstrom B., Miranda J., Paules Ch. et al. Hemopexin and a1-microglobulin heme scavengers with differential involvement in preeclampsia and fetal growth restriction. PLoS One. 2020; 15(9) e 0239030. https://dx.doi.org/10.1371/journal.pone.0239030.
  69. Brosnan M.E., Brosnan J.T. Hepatic glutamate metabolism: A tale of 2 hepatocytes. Am. J. Clin. Nutr. 2009; 90(3): 857-61. https://dx.doi.org/10.3945/ajcn.2009.27462Z.
  70. Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 2011; 17(4): 448-53. https://dx.doi.org/10.1038/nm.2307.
  71. Feig D.S., Shah B.R., Lipscombe L.L., Wu C.F., Ray J.G. et al. Preeclampsia as a risk factor for diabetes: a population-based cohort study. PLoS Med. 2013; 10(4): e1001425. https://dx.doi.org/10.1371/journal.pmed.1001425.
  72. Nobakht M.Gh.B.F. Application of metabolomics to preeclampsia diagnosis. Syst. Biol. Reprod. Med. 2018; 64(5): 324-39. https://dx.doi.org/10.1080/19396368.2018.1482968.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies